Clearside Biomedical rises on U.S. launch of eye therapy

Clearside Biomedical,

28/03/2022 14:38

** Shares of drug developer  CLSD.O  up 5.1% at $2.48
    ** Co and Bausch + Lomb report U.S. commercial launch of eye
therapy, XIPERE  urn:newsml:reuters.com:*:nPn3Z8wWHa
    ** Bausch + Lomb is the eye health business of Bausch Health
Co  BHC.N 
    ** XIPERE is used to treat macular edema or build-up of
fluid in the central area of retina, associated with an eye
disease called uveitis
    ** CLSD stock lost ~14% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))